Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
04 mai 2023 16h05 HE
|
Immuneering Corporation
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05 mars 2023 18h30 HE
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Immuneering Announces Participation in March Investor Conferences
28 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
SAI.TECH Announces Sponsorship and Presence on the 2022 Cryptocurrency Research Conference
19 sept. 2022 08h00 HE
|
SAI.TECH Global Corporation
SINGAPORE, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Today, SAI.TECH Global Corporation ("SAI.TECH" OR "SAI", NASDAQ: SAI), a global energy-saving bitcoin mining operator and a clean-tech company that...
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
13 juin 2022 07h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...
Verano Founder and Chief Executive Officer George Archos and Chief Operating Officer Darren Weiss Share Celebratory Comments on New Jersey Cannabis Regulatory Commission’s Approval of Personal Use Cannabis Sales
11 avr. 2022 16h21 HE
|
Verano Holdings Corp.
CHICAGO, April 11, 2022 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today shared executive commentary...
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
21 mars 2022 08h00 HE
|
Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
17 nov. 2021 09h15 HE
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
29 oct. 2020 16h36 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
28 sept. 2020 08h45 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...